- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 10 Best US Penny Stocks to Buy. On December 5, Piper Sandler reaffirmed its Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with a price target of $6.50. Also on December 5, H.C. Wainwright reiterated its Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with a price target of $10. This update comes as the company approaches an important data readout for its CX-2051 therapy in colorectal cancer. H.C. Wainwright outlined specific performance b ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 12 best multibagger stocks to buy heading into 2026. Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress As of December 18, 2025, 90% of analysts are bullish on CytomX Therapeutics, Inc. (NASDAQ:CTMX), setting a median price target of $6.50. This translates into a healthy upside potential of 58.20%. On December 5, 2025, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw H.C. Wainwright reiterate its “Buy” rating wit ...

In this article, we discuss the 12 Best Multibagger Stocks to Buy Heading into 2026.As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year. Even more importantly, they are wondering where the next wave of massive returns may emerge.So, before we jump onto our list of the 12 Best Multibagger Stocks to Buy Heading into 2026, we attempt to frame the broader market backdrop through the lens of leading Wall Street expectati ...

Core Insights - CytomX Therapeutics (CTMX) is approaching a significant trial readout for CX-2051, an antibody-drug conjugate being evaluated for colorectal cancer [1] Group 1: Company Overview - CTMX was rated a buy in October, indicating positive sentiment towards the stock ahead of the trial results [1] Group 2: Industry Context - The focus is on trading around key events such as trial results and regulatory approvals, highlighting the volatility and potential investment opportunities in the biotech sector [1]

CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Event**: FY Conference held on December 04, 2025 - **Key Technology**: Probody technology, which masks therapeutic proteins to enhance targeting in tumor tissues while reducing effects on healthy tissues [1][3][4] Core Points and Arguments Probody Technology - Probody technology allows for selective binding of therapeutic proteins in tumor tissues by masking them, which is cleaved by tumor-associated proteases [3][4] - This innovative approach has been validated through encouraging phase one data on CX-2051 for colorectal cancer [1][2] CX-2051 Development - CX-2051 targets EpCAM, a tumor antigen abundant in colorectal cancer, but previously faced challenges due to toxicity in normal tissues [6][7] - The phase one study showed a confirmed response rate of 28% in a late-stage metastatic colorectal cancer patient population, with a median of four prior therapies [10][11] - The drug demonstrated a progression-free survival of 5.8 months and a 94% disease control rate, indicating significant efficacy in a difficult-to-treat population [11] Future Development Plans for CX-2051 - The company plans to expand the study to include about 100 patients and aims to provide updates on efficacy and safety in Q1 of the following year [12][13] - The immediate goal is to get CX-2051 on a path to registration as a monotherapy, with potential studies against standard care in later lines of therapy [15][17] - There is a vision for CX-2051 to potentially replace irinotecan in earlier lines of colorectal cancer therapy [16][17] CX-801 Development - CX-801, a masked interferon alpha-2b, is being developed for melanoma, leveraging the same masking strategy to improve tolerability while activating the immune response [21][22] - Early data showed activation of interferon-responsive genes and recruitment of T cells in the tumor microenvironment, setting the stage for combination therapy with Keytruda [24][25] Other Programs and Partnerships - CytomX is also exploring CX-908, a dual masked T cell engager targeting P-cadherin and CD3, with promising preclinical results [26][27] - The company is open to partnerships for further development, especially in the T cell engager space, while maintaining a focus on productization [28][29] Financial Position - As of the end of Q3 2025, CytomX had $144 million in cash, which has since increased to approximately $158 million, providing funding into Q2 2027 [33] - This financial position supports ongoing clinical studies and the expansion of their therapeutic pipeline [33] Additional Insights - The company has experienced a transformational year in 2025, with significant advancements in their clinical programs and technology validation [5][33] - There is a strong emphasis on maintaining urgency and speed in development, with potential for broadening the application of their Probody platform across various solid tumors [18][30]

CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Focus**: Pioneering protease-based masking of therapeutic antibodies and biologics, particularly in oncology Key Points Colorectal Cancer Data - **Product**: CX2051, an antibody-drug conjugate (ADC) targeting EpCAM, specifically designed for late-line colorectal cancer (CRC) treatment [2][3] - **Phase 1 Data**: Initial data showed a 28% confirmed response rate in late-stage CRC patients with a median of four prior therapies [4][10] - **Patient Enrollment**: Expanded from 25 to 100 patients in the phase 1 study, with a focus on evaluating 73 to 100 patients for efficacy [5][10] Dose Escalation and Safety - **Dose Levels**: Current doses being evaluated are 7.2, 8.6, and 10 mg/kg, with no dose-limiting toxicities (DLTs) reported to date [9][10] - **Response Rate Expectations**: Current treatment options for late-stage CRC have low response rates; CytomX aims to demonstrate superior efficacy with CX2051 [10][11] Future Development Plans - **Next Steps**: Plans to initiate a combination study with bevacizumab (Bev) in Q1 2026, and potentially a registrational study in the fourth line of therapy against fruquintinib [13][14] - **Additional Indications**: Exploring the use of CX2051 in other solid tumors, including gastric and pancreatic cancers, as EpCAM is highly expressed in these types [15] Competitive Landscape - **Market Position**: CX2051 is the first anti-EpCAM ADC developed, with other competitors in the topo-based ADC space showing promise but not matching the initial data from CytomX [18][20] Other Programs - **CX-801 Program**: A masked interferon alpha-2b designed to enhance the immune response while minimizing systemic side effects, with plans for combination studies with Keytruda in late-stage melanoma [21][22] - **Therapeutic Window**: The goal is to improve tolerability and efficacy of established therapies through innovative masking technology [23] Data Presentation - **Upcoming Data Reveal**: Anticipated updates on the 100 patient study in Q1 2026, with a focus on determining optimal dosing and safety profiles [25][26] Conclusion CytomX Therapeutics is positioned to make significant advancements in the treatment of colorectal cancer and other solid tumors through its innovative ADC technology and strategic development plans. The company is actively expanding its clinical trials and exploring new indications, while maintaining a competitive edge in the oncology market.

Core Insights - The article discusses the current investment landscape for penny stocks, emphasizing that their performance is influenced more by market psychology than macroeconomic conditions [1] - Small-cap stocks are gaining momentum, particularly after strong third-quarter earnings, making them more attractive compared to large-cap stocks [2] - Several catalysts are driving interest in small-cap stocks, including M&A activity, biotech developments, and opportunities in sectors linked to AI [3] Small-Cap Stock Performance - The Russell 2000 index has increased by 21.60% over the past six months, although it has experienced four consecutive weeks of decline recently [4] Methodology for Stock Selection - The list of 12 hot penny stocks was compiled based on stocks priced under $5, with over 50% returns in the last three months and an upside potential exceeding 20% as of November 24, 2025 [6] - Hedge fund sentiment was also considered, utilizing data from Insider Monkey's hedge fund database tracking 983 hedge funds as of Q2 2025 [7] Individual Stock Highlights - **Shattuck Labs, Inc. (NASDAQ:STTK)**: - 3-month performance of 102.21% with an average upside potential of 45.63% [9] - The company has a cash balance of $86.10 million and reported a net loss of $10.1 million for Q3 2025 [10][11] - **Erasca, Inc. (NASDAQ:ERAS)**: - 3-month performance of 93.08% with an average upside potential of 73.01% [13] - The company reported a net loss of $30.6 million for Q3 2025 but has a solid cash position of $362.4 million [15][17] - **CytomX Therapeutics, Inc. (NASDAQ:CTMX)**: - 3-month performance of 107.50% with an average upside potential of 78.09% [18] - The company reported a revenue decline to $6 million for Q3 2025 but maintains a cash balance of $143.6 million [20][21]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localizing treatment to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] Clinical Pipeline - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in various EpCAM-expressing epithelial cancers, including colorectal cancer (CRC), and was developed in collaboration with ImmunoGen [3] - CX-801 is designed for broad applicability in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [2] - A live webcast of the presentations will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2]